Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines.
Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, Benicar HCT, Azor and Tribenzor.
The accord, under which the Tokyo-based company didn't admit wrongdoing, comes more than two years after it paid $39 million to resolve the U.S. government's allegation that it had paid illegal kickbacks to doctors who prescribed the medicines.